Travere Therapeutics Signs Deal to License Potential Kidney Disease Drug From Everest Medicines

MT Newswires Live06-02 19:45

Travere Therapeutics (TVTX) said Tuesday it has signed an exclusive agreement to license civorebrutinib, a potential treatment for immune-mediated kidney diseases, including primary membranous nephropathy, from Everest Medicines.

Under the agreement, Everest will receive an upfront payment of $112.5 million for granting Travere exclusive development and commercialization rights to civorebrutinib outside China and certain East and Southeast Asian countries, Travere said.

Travere said that Everest can receive up to an additional $1.03 billion upon meeting certain clinical development, regulatory and commercial milestones across up to five indications.

Travere said it will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640910644?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640910644","market":"fut","top_or_hot":-1,"title":"Travere Therapeutics Signs Deal to License Potential Kidney Disease Drug From Everest Medicines","media":"MT Newswires Live","content":"<html><body><p> Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVTX) said Tuesday it has signed an exclusive agreement to license civorebrutinib, a potential treatment for immune-mediated kidney diseases, including primary membranous nephropathy, from Everest Medicines.</p><p>Under the agreement, Everest will receive an upfront payment of $112.5 million for granting Travere exclusive development and commercialization rights to civorebrutinib outside China and certain East and Southeast Asian countries, Travere said.</p><p>Travere said that Everest can receive up to an additional $1.03 billion upon meeting certain clinical development, regulatory and commercial milestones across up to five indications.</p><p>Travere said it will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Signs Deal to License Potential Kidney Disease Drug From Everest Medicines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Signs Deal to License Potential Kidney Disease Drug From Everest Medicines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-02 19:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVTX) said Tuesday it has signed an exclusive agreement to license civorebrutinib, a potential treatment for immune-mediated kidney diseases, including primary membranous nephropathy, from Everest Medicines.</p><p>Under the agreement, Everest will receive an upfront payment of $112.5 million for granting Travere exclusive development and commercialization rights to civorebrutinib outside China and certain East and Southeast Asian countries, Travere said.</p><p>Travere said that Everest can receive up to an additional $1.03 billion upon meeting certain clinical development, regulatory and commercial milestones across up to five indications.</p><p>Travere said it will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FFTY","symbol_name":"Innovator IBD 50 ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640910644","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640910644","pubTimestamp":1780400743,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Travere Therapeutics (TVTX) said Tuesday it has signed an exclusive agreement to license civorebrutinib, a potential treatment for immune-mediated kidney diseases, including primary membranous nephrop","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FFTY":"Innovator IBD 50 ETF","BK4539":"次新股","BK4007":"制药","TVTX":"Travere Therapeutics, Inc.","MDCO":"麦迪逊医药","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Travere Therapeutics签署Everest Medicines潜在肾病药物许可协议","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FFTY":1.5,"TVTX":1,"LENZ":1.5,"MDCO":1.5},"content_text":"Travere Therapeutics (TVTX) said Tuesday it has signed an exclusive agreement to license civorebrutinib, a potential treatment for immune-mediated kidney diseases, including primary membranous nephropathy, from Everest Medicines.Under the agreement, Everest will receive an upfront payment of $112.5 million for granting Travere exclusive development and commercialization rights to civorebrutinib outside China and certain East and Southeast Asian countries, Travere said.Travere said that Everest can receive up to an additional $1.03 billion upon meeting certain clinical development, regulatory and commercial milestones across up to five indications.Travere said it will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640910644","isCrawlerRequest":true}